This website is intended for US healthcare audiences only. If you are seeking global VELTASSA information, please click here.
VELTASSA® (patiromer) for oral suspension
Important Safety Information INDICATION
VELTASSA is indicated for the treatment of hyperkalemia. Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.
WARNINGS AND PRECAUTIONS Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies. Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.
MOST COMMON ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnesemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.
Full Prescribing Information Patient Site Patient Support Services

Vifor Pharma can help your patients access and afford VELTASSA

FINANCIAL ASSISTANCE OPTIONS

Commercially insured patients may pay as low as $0 for VELTASSA*
co-pay image
  • Instant savings at the pharmacy
  • No co-pay card or print coupon required
  • No patient registration
Uninsured and non-commercially insured patients

Additional Financial Support

If patients need help paying for VELTASSA, Veltassa Konnect may be able to help: see more information below.

*Program is for commercially insured patients. Patients enrolled in a government health insurance program such as Medicare Part D, Medicaid, TRICARE, or Veterans Health Administration are not eligible; this is not an exhaustive list of excluded government health plans. Patients may pay as low as $0 for up to 12 months; after that, renewal is required. The patient is responsible for applicable taxes. Annual maximum limits apply. Co-pay program is not insurance. No party may seek reimbursement for any part of the co-pay benefit received under the program. See full Terms and Conditions below.

Uninsured and non-commercially insured patients

Additional Financial Support

If patients need help paying for VELTASSA, Veltassa Konnect may be able to help: see more information below.

Help your patients get access with prior authorization (PA) support

covermymeds

96% of payers use electronic PAs (ePAs)1

Average median turnaround time for VELTASSA ePAs: ~45 minutes2

CoverMyMeds is a NO-COST online portal that helps your practice quickly find and submit PA forms:

Log in to covermymeds.com and search for VELTASSA
Initiate and submit an ePA
  • On average, prospective ePAs led to patients’ receiving their medications ~13 days faster relative to retrospective ePAs in a health system case study1
Appeal support is available, if needed
Register online or chat live at covermymeds.com, or call 866-452-5017

Veltassa Konnect may help patients
start and stay on therapy

Veltassa Konnect

Enroll your patients with the Veltassa Konnect Enrollment Form

Veltassa Konnect helps by providing full patient support services:

Trial supply

VELTASSA Starter Supply

  • A free 20-day trial supply of VELTASSA
Access support

Access & Insurance Support

  • Case Management to help patients and their healthcare providers understand patients’ insurance coverage for VELTASSA, including information on PAs and appeals
  • Counseling on financial assistance options for patients
  • Specialty pharmacy ships prescriptions to patients directly
Financial assistance

Patient Assistance Program (free drug)

  • The VELTASSA Patient Assistance Program provides VELTASSA for free to patients who meet program eligibility criteria:
Medicare patients who are unable to afford their co-pay for VELTASSA
Patients who are uninsured / have no insurance
Insured patients who have a denied appeal for coverage
Ongoing support

Ongoing Support

  • Stay-on-Track, an adherence program, offers patients ongoing support and lifestyle tips
  • Nurse advocates are available to answer patients’ product-specific questions
  • Patients can enroll online at https://www.veltassa.com/patient/registration/

Use of Veltassa Konnect program is not a guarantee of payment or reimbursement. Coverage is subject to individual
insurance plans, which may vary.

The VELTASSA Starter Supply Program is not contingent on purchase. This is a one-time-only supply and may be subject to additional restrictions. There is no guarantee that VELTASSA will be approved by patients’ health plans.

Veltassa Konnect does not provide medical advice. Patients should consult their healthcare professional if they have any questions about their health or treatment.

Enroll your patients in Veltassa Konnect today

Please contact Veltassa Konnect at 1-844-870-7597, Monday through Friday, 9 AM to 8 PM ET for additional information about the program and how your patients can access VELTASSA

Veltassa Konnect Enrollment Form can help expedite access
to VELTASSA for your patients

DOWNLOAD FORM IN ENGLISH DOWNLOAD FORM IN SPANISH

$0 Co-pay Important Terms and Conditions

By participating in Vifor Pharma, Inc.’s $0 Co-pay Savings Program (”Co-pay Program”) for VELTASSA, the patient acknowledges that, at the time of usage, they meet the eligibility criteria and comply with the following terms and conditions.

The Co-pay Program is for commercially insured patients. Patients with prescription coverage through any type of federal or state government-funded program are not eligible (eg, Medicare, Medicaid, TRICARE, Veterans Administration [VA], Mi Salud).

The patient may pay as low as $0 per month for up to a 12-month period, and afterward renewal is required. Annual maximum limits may apply. The Co-pay Program for VELTASSA is not insurance. Vifor Pharma, Inc. reserves the right to rescind, revoke, or amend this program without notice. The patient must use the Co-pay Program for a valid prescription of VELTASSA, and this cannot be combined with any other coupon, trial, savings card, free drug assistance, or other offer.

Patient must live in the United States (including the District of Columbia, Puerto Rico, and the U.S. Virgin Islands). If the patient is enrolled in Veltassa Konnect, patient is required to promptly inform Veltassa Konnect of any change in insurance status during the course of enrollment.

The patient and participating pharmacy are each obligated to inform the insurance plan of any benefit received under the Co-pay Program as required and may not participate if the Co-pay Program conflicts with the plan’s policy. No party may seek reimbursement for any part of the benefit received by patient under the Co-pay Program. The patient is responsible for applicable taxes. Limit one per person; offer is non-transferable and void where prohibited by law or restricted.

Important Safety Information, including Boxed WARNING

Indication

VELTASSA is indicated for the treatment of hyperkalemia.
Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.


Important Safety Information

CONTRAINDICATIONS
  VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

 

WARNINGS AND PRECAUTIONS
  Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

MOST COMMON ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnesemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.

Please click here for full Prescribing Information.



References: 1. Medication Access Report. covermymeds.com. https://www.covermymeds.com/main/medication-access-report/. Accessed December 3, 2020. 2. Data on file as of September 2020. Vifor Pharma, Inc.

Indication

VELTASSA is indicated for the treatment of hyperkalemia. Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

Important Safety Information

CONTRAINDICATIONS VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.
WARNINGS AND PRECAUTIONS
Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies. Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels. MOST COMMON ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnesemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.